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Summary To date, cytogenetic studies on pancreatic carcinoma are rare, and little is known about the frequency of cytogenetic aberrations
in primary carcinomas compared with metastatic tumour cells. We therefore evaluated the frequency of chromosomal aberrations in 12
primary pancreatic carcinomas and in effusion specimens from 25 patients with pancreatic cancer by using interphase fluorescence in situ
hybridization (FISH) and a panel of four centromeric probes. Hyperdiploidy and chromosomal imbalances, predominantly affecting
chromosome 8, were a constantfinding in metastatic effusion cells, whereas concordant gain of chromosomes or relative loss of chromosome
18 characterized primary pancreatic carcinomas. The potential role of oncogenes located on chromosome 8 for pancreatic cancer
progression was further investigated by double-hybridization studies of aneuploid effusion cells with a probe to 8q24 (MYC) and a centromeric
probe to chromosome 8, which demonstrated amplification of the MYConcogene in two of ten cases (20%). Finally, a potential application of
basic findings in the clinical setting was tested by searching for micrometastatic cells in effusions from pancreatic cancer patients primarily
negative by FISH. Two-colour FISH in combination with extensive screening (>10 000 nuclei) seems to be a useful tool to unequivocally
identify micrometastatic cells by demonstrating hyperdiploidy and intranuclear chromosomal heterogeneity.
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So far, 90 exocrine and endocrine pancreatic cancers have been
karyotyped successfully (larger series on exocrine pancreatic
carcinoma: Johansson et al, 1992; Bardi et al, 1993; Griffin et al,
1994, 1995; smaller series or case reports on exocrine orendocrine
pancreatic tumours: van der Riet-Fox et al, 1979; Bullerdiek et al,
1985; Casalone et al, 1987; Teyssier, 1987; Scappaticci et al, 1992;
Bardi et al, 1994; Bugalho et al, 1994; Danner et al, 1994; Long et
al, 1994; Gorunova et al, 1995; Wiley et al, 1995; Grant et al,
1996). Considering the data available, loss of chromosome 18 is
the most common numerical aberration identified by metaphase
cytogenetics, occurring in half of the exocrine tumours with an
abnormal karyotype. By comparative genomic hybridization,
Solinas-Toldo et al (1996) demonstrated loss on 18q in 3 of 27
exocrine pancreatic cancers and Fukushige et al (1997) in five of
six primary carcinomas and 10 of 12 cell lines. Recently, the
tumour-suppressor gene DPC4 was identified as the primary target
ofthese aberrations (Hahn et al, 1996).
Besides chromosome 18, numerical aberrations in exocrine
pancreatic tumours were reported to frequently involve chromo-
somes 7, 11, 12 and 20. Fluorescence in situ hybridization (FISH)
with chromosome-specific probes can be used to visualize chromo-
somal aberrations ofindividual nuclei from paraffin-embedded and
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methanol-acetic acid-fixed material, thus allowing retrospective
analysis ofarchived material. To delineate numerical chromosomal
status of pancreatic carcinomas and to identify chromosomal
patterns associated with pancreatic tumour progression, we
performed double-hybridization experiments with a panel of four
centromeric probes (chromosomes 7, 8, 11 and 18) in 12 primary
pancreatic carcinomas and effusion specimens from 25 patients
with pancreatic cancer. Gain ofchromosomes 7 and 11 and loss of
chromosome 18 are frequent findings by metaphase karyotyping in
exocrine pancreatic tumours, thus providing the background for
FISH analysis of these chromosomes. As chromosome 8 is
frequently aberrant in primary and metastatic breast cancer (Roka
et al, 1998) andplays a role in prostate cancerprogression (Jenkins
etal, 1997), we additionally selected acentromere-specific probe to
this chromosome to analyse numerical aberrations ofchromosome
8 and theirpotential significance forpancreatic cancerprogression.
In addition to pancreatic adenocarcinomas, four endocrine tumours
ofthe pancreas were analysed by interphase FISH.
Finally, the potential impact of aneuploidy detection by FISH
for the identification ofpancreatic (micro-)metastatic cells in effu-
sions was evaluated, using an approach previously performed in
breast cancer effusions (Roka et al, 1998; Zojer et al, 1997).
MATERIALS AND METHODS
Clinical material
Paraffin-embedded tissue sections from 16 patients undergoing
surgery for pancreatic tumours (1986-1995) were obtained from
the Department of Clinical Pathology (University of Vienna) or
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the Department of Pathology of the Vienna Donauspital. These
specimens comprised eight ductal adenocarcinomas, three peri-
ampullary carcinomas, one mucinous cystadenocarcinoma of the
pancreas and four endocrine tumours ofthe pancreas (one gastrin,
one insulin, one glucagon and one non-secretory tumour).
Preparation of the primary tumours followed the protocol
detailed by Ott et al (1997). Briefly, 20-gm sections were cut from
paraffin-embedded tissue blocks, dewaxed in xylene and rehy-
drated in graded alcohols. Subsequently, single-cell suspensions
were obtained by digestion with 1 mg ofproteinase XXIV (Sigma,
Deisenhofen, Germany) in 2 ml of Carlsberg solution (0.1 M Tris
buffer, 0.07 M sodium chloride, pH 7.2) for 1 h and then dropped
onto a glass slide. To enhance probe accessibility to the nucleus,
cells were incubated at 80°C in 1 M sodium thiocyanate and at
37°C in 0.4% Pepsin (in 0.2 N hydrochloric acid) for 1 and 3 min
respectively.
Cells from 22 ascitic and three pleural effusions from patients
with pancreatic cancer were gained by centrifugation of native
effusion specimens, washed twice in phosphate-buffered saline,
fixed in methanol-acetic acid (3:1) and stored at-80°C.
FISH procedure and microscopy
The FISH protocol followed the standard procedure in our labora-
tory, as described in detail in a previous report (Drach et al, 1995).
Directly, fluorescence-labelled alpha satellite probes (Vysis,
Downers Grove, IL, USA), specific for the centromeric regions of
human chromosomes 7, 8, 11 and 18, were applied. Two-colour
FISH was performed using Spectrum Green-labelled probes in
combination with Spectrum Orange-labelled probes, with chromo-
some 18 always being a partner in these combinations.
At least 200 non-overlapping nuclei from each effusion spec-
imen and at least 100 nuclei from each primary tumour were evalu-
ated by fluorescence microscopy (Olympus AH-3 microscope).
Photographic documentation was performed using a Kodak Ekta-
chrom 1600 film. In addition, images were acquired using acooled,
charged, coupled device (CCD) camera (Photometrics, Tucson,
AZ) mounted on a Zeiss-Axioplan-2 immunofluorescence micro-
scope and the Quips-XL FISH-imaging software (Vysis).
Control specimens and criteria for true aneuploidy
Cut-off values for detection of true aneuploidy were calculated as
mean signal numbers + three standard deviations of control cells
from normal pancreatic tissue (n = 1) and chronic pancreatitis
(n = 2) in the case of primary tumours; four effusion specimens
from patients with non-malignant diseases served as controls for
metastatic effusion cells.
Mean chromosome copy numbers for each tumour specimen and
chromosome, whichby definition are calculated by dividing the sum
of the centromeric signals with the number of nuclei scored, are
listed in Tables 1 and 2. Only nuclei aneuploid by two-colour FISH
analysis were considered forcalculation ofmean copy numbers, and
disomic cells (with a pattern of2/2 signals for the Spectrum Green/
Spectrum Orange probe pair) were skipped from analysis. Concern-
ing the nuclear status of 1/1-signal, 1/2-signal and 2/3-signal cells
(or vice versa), only percentages of cells above cut-off were
included in the calculation ofmean copy numbers. Forevaluation of
malignant effusions, acut-offfor3/4- and4/4-signal cells was estab-
lished, as a small population of mesothelial cells with this chromo-
somal pattern was found in control effusions (Fiegl et al, 1996).
Definitions of modal ploidy and chromosomal
imbalances
A modal ploidy status for a tumour specimen was determined ifat
least three of the four chromosomes showed mean copy numbers
in the range of one ploidy unit, allocating the tumour to the corre-
sponding ploidy category (triploidy, tri-tetraploidy, tetraploidy
etc., see Tables 1 and 2). If all four chromosomes showed mean
copy numbers in the range of one ploidy unit, no chromosomal
imbalances were indicated (see Table 1). In the other case, devia-
tion of the fourth chromosome was indicated as loss or gain. If
less than three chromosomes showed mean copy numbers in the
defined range, the chromosomal status was termed heterogeneous.
Imbalances were predominant in these cases and a distinct ploidy
was not evident. Similar criteria for characterization ofploidy and
chromosomal imbalances were used in a FISH study of squamous
cell carcinomas of the head and neck (Soder et al, 1995).
Furthermore, we analysed three pancreatic carcinoma cell lines
(BxPC-3, PANC-1, AsPC-1; all obtained from America Type
Culture Collection (ATCC), Rockville, Maryland) using FISH and
fourcentromeric probes. Ploidy estimated on the basis ofthe FISH
results was in good agreement with the ploidy defined by
metaphase karyotyping (data provided in the ATCC catalogue).
MYC amplification in aneuploid effusions
In additional experiments, a Spectrum Orange-labelled probe to
8q24 (MYC) was used in combination with a Spectrum Green-
labelled probe to the chromosome 8 centromere. Amplification of
the MYC oncogene was defined as the presence ofmore than 20%
of cells with over-representation of MYC signals in relation to
chromosome 8 signals (Jenkins etal, 1997). At least 100 non-over-
lapping nuclei from each of the ten aneuploid effusion specimens
were evaluated. Two effusion cell samples from patients with non-
malignant diseases served as controls for the MYC studies.
Micrometastatic cell detection
In effusion specimens with no detectable aneuploidy by the stan-
dard signal scoring procedure (n = 15), 1-2 x 104 nuclei (corre-
sponding to 200 fields with 50-100 cells) were screened for the
occurrence ofrare aneuploid cells (as detailed previously; Roka et
al, 1998). This is a procedure potentially practicable in the routine
setting as, when in situ hybridization is appropriately performed
(our laboratory set a minimum standard at 90% hybridization effi-
ciency), it does not take more than 30 min to screen >10 000
nuclei. In this series, two-colour FISH with probe pairs ofchromo-
somes 7/8 and 11/18 was performed, and rare grouped or single
cells exhibiting more than four signals and concomitantly showing
intranuclear chromosomal heterogeneity (e.g. a signal pattern of
5/2) were considered as unequivocal indicators ofmalignancy.
RESULTS
Chromosomal status of primary and metastatic
pancreatic carcinoma
Significantdifferences were found by comparing the chromosomal
status of primary carcinomas (neuroendocrine tumours were
excluded from this comparative analysis) with that of metastatic
specimens (Tables 1 and 2). A hyperdiploid modal ploidy status
was observed in all primary carcinomas. Concordant gains of
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Table 1 Chromosomal status of primary pancreatic carcinomas (P1-P12) and neuroendocrine tumours of the pancreas (P13-P6)
Chromosome copy number
No. Histologya Stageb A (%)c Ploidy 7 8 11 18d Imbalance
P1 DA T3N1M1 44.6 Tri-tetr 3.8 3.6 3.7 3.8
P2 DA T3N1MO 38.2 Tetr 3.8 3.8 4.2 3.6m
P3 DA T3N1M0 20.7 Tri-tetr 3.8 3.1m 3.5 3.6
P4 DA T4N1MO 59.4 Tri-tetr 3.3 3.5 3.7 3.6
P5 PA T2NOM0 24.4 Tri 3.1 3.0 NSA 2.4
P6 DA T2N1MO 33.8 Tri 3.2 3.1 3.4 2.8
P7 MC T2NOM0 23.0 Het 3.9 2.0 2.0 3.3 Het
P8 DA T2N1MO 76.6 Tetr 4.2 2.5m 3.8 3.5 -8
P9 DA T2N1MO 29.9 Tetr 4.2 3.7 4.1 6.4 +18
PlO PA T1NXMO 39.0 Di-tri 2.4 3.0 2.3 1.8M -18
P11 PA T2NOM0 46.3 Tri-tetr 3.4 3.8 3.3 2.1M -18
P12 DA T4N1M0 36.6 Tri 3.2 2.8 3.4 2.3 -18
P13 NE (NS) T2NOM0 75.6 Het 3.7 1.9m 1.3m 3.2 Het
P14 NE (GA) T2N1MO 36.2 Tri-tetr 3.8 3.2 3.2 2.5m -18
P15 NE (GL) T1N1MO 61.0 Tri 3.1 2.8 1.9m 2.6m -11
P16 NE (IN) T1NXMO 68.6 Haploid 3.6 1.5 M 1.9m 1.6 M +7
aDA, ductal adenocarcinoma; PA, periampullary carcinoma; MC, mucinous cystadenocarcinoma; NE, neuroendocrine tumour; NS, non-secretory; GA,
gastrinoma; GL, glucagonoma; IN, insulinoma; as classified by immunohistochemistry. bTNM classification of exocrine pancreatic tumours is also applied for
neuroendocrine tumours of the pancreas. cPercentage of non-disomic cells (signal pattern not equal to 2/2). dMean value of chromosome 18 copy numbers in
three double-hybridization experiments. Het, heterogenous chromosomal status; m, subpopulation of tumour cells with monosomy for the respective
chromosome; M, main population of tumour cells (>50%) exhibits monosomy for the respective chromosome; NSA, no significant aneuploidy.
Table 2 Chromosomal status of malignant effusion cells from patients with pancreatic carcinoma (El-EIO) and comparison of FISH results with classification
of effusions by cytological examination (E1-E25)
Chromosome copy number
No. Sitea Cytology A(%)b Ploidy 7 8 11 180 Imbalance
E1 A Positive 13.7 Hex 6.5 4.2 6.7 5.9 -8
E2 A Positive 21.2 Pent 4.9 2.1 4.5 4.9 -8
E3 P Positive 24.7 Het 3.5 4.7 3.9 2.1 Het
E4 A Positive 12.8 Tri-tetr 3.5 3.8 3.3 2.0 -18
E5 A Positive 13.6 Tri-tetr 3.3 4.4 3.8 3.2 +8
E6 A Positive 18.8 Tetr 3.4 5.6 4.4 4.2 +8
E7 A Positive 73.5 Tri 3.2 4.2 3.3 3.1 +8
E8 A Negative 10.6 Tetr NSA 6.6 4.1 4.0 +8
E9 A Positive 8.6 Di-tri 3.9 NSA NSA 2.9 +7
E10 P Positive 8.5 Het 5.6 3.7 2.4 2.9 Het
Eli A Positive Three islets (six aneuploid cells)d
E12 A Positive Two islets (13 aneuploid cells)d
E13 A Positive Five single aneuploid cellsd
E14 A Negative Two islets (23 aneuploid cells)d
E15 A Negative Three islets (four aneuploid cells)d
E16-25 9A/1P Negative No aneuploidy
aA, ascites; P, pleural effusion. bPercentage of non-disomic cells (signal pattern not equal to 2/2). cMean value of chromosome 18 copy numbers in three double-
hybridization experiments. Het, heterogenous chromosomal status; NSA, no significant aneuploidy. dRare aneuploid cells as detected by extensive screening.
signal number for all chromosomes examined were found in 6 of
12 cases and no chromosomal imbalances were indicated in these
tumours (P1-P6). In contrast, chromosomal imbalances were iden-
tified in all metastatic carcinoma specimens (P < 0.01, X2-test),
with chromosome 8beingpredominantly affected (seeFigure IA).
Chromosome 8 imbalances were found in six of ten metastatic
specimens in our series (four gains and two losses), a frequency
(60%) that is significantly different (P < 0.01, X2-test) to the
frequency of chromosome 8 imbalances in primary carcinomas
(1of 12 specimens or 8%, see Table 1).
Monosomy 18 was observed in two primary pancreatic carci-
nomas (PI10 and P11) that were resected at anearly stage oftumour
progression (TINXMO and T2NOMO), which is indicative of loss
of chromosome 18 being an early event in pancreatic carcino-
genesis. In three other primary tumours, small subpopulations
of cells with monosomy 8 or monosomy 18 were identified, as
indicated in Table 1. However, no monosomic cells were found in
the metastatic specimens.
In contrast, there was a trend towards higher chromosome copy
numbers in metastatic disease. Ploidy of two effusion specimens
(El and E2) was designated pentaploid and hexaploid, respec-
tively, and gains of individual chromosomes, with mean copy
numbers in the pentasomic to hexasomic range, were observed in
three other effusions (E6, E8, E1O).
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Figure 1 (A) In effusion specimen El, nuclei with five to seven signals for chromosome 18 (red) and three to four signals for chromosome 8 (green) are
present, indicative of relative loss of chromosome 8 in this specimen (see also Table 1). (B) In nucleus (left) from effusion E2, MYC amplification is
demonstrated by the presence of five red signals for 8q24 (MYC) in relation to only two signals for the centromere of chromosome 8 (green). Nucleus to the
upper right shows normal signal pattern. (C) In effusion Eli, rare aneuploid cells were detected by screening of >10 000 nuclei, as exemplified in this figure. Aneuploid nucleus with six signals for chromosome 7 (red) and five signals for chromosome 8 (green) is surrounded by a population of lymphocytes. Hyperdiploidy and concomitant intranuclear chromosomal heterogeneity indicates malignancy
Chromosomal status of endocrine pancreatic tumours
Chromosomal status of endocrine tumours was different to that
observed in adenocarcinomas. Chromosomal imbalances with
monosomic cell populations were a feature of all four endocrine
tumours studied (see Table 1). One tumour (N4) was designated
haploid because ofthe predominance ofnuclei with monosomy of
chromosomes 8, 11 and 18. This finding is in line with a previous
study (Long et al, 1994), in which near-haploid clones were identi-
fied in two endocrine neoplasms of the pancreas by metaphase
karyotyping.
MYC studies
Two out of ten malignant pancreatic effusion specimens (20%)
showed MYC amplification, as defined in the Materials and
methods section. High-level amplification, with a MYC-
centromere 8 ratio >2, was observed in effusion E2 (in 32.6%
ofall nuclei counted, see Figure IB), which additionally exhibited
relative loss ofchromosome 8 as indicated in Table 1. On the other
hand, effusion specimen E7 was characterized by a relative gain of
chromosome 8 in association with a low level ofMYC amplifica-
tion (with aMYC-centromere 8 ratio of 1.1-2 in 36.9% ofnuclei).
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In the two control effusions, MYC was over-represented in rela-
tion to chromosome 8 in less than 2% ofcells evaluated.
FISH as a diagnostic tool to detect micrometastatic
cells
We have shown previously that FISH using centromeric probes
can improve malignant cell detection in effusions from breast
cancerpatients (Zojer et al, 1997). In the present study, we investi-
gated whether or not this is also true for patients with pancreatic
cancer by comparing the results of cytological examination of 22
ascitic and three pleural effusion specimens with the FISH results.
Twelve out of 25 effusion specimens (48%) were classified as
malignant by cytological examination, whereas 15 of 25 (60%)
were considered to be aneuploid, as analysed by FISH in a blinded
fashion (P = NS, X2-test). Concordant classification by cytology
and FISH was achieved in 22 of 25 cases. However, in three
cytologically negative effusions, aneuploidy above background
(E8) or rare aneuploid cells (E14, E15) could be detected by two-
colour FISH. All samples with disomic results by FISH (n = 10)
were also negative for malignant cells on cytological examination.
In effusions El1-EI5, which were classified as disomic by
FISH based on analysis of 200 cells, rare aneuploid cells and thus
malignancy could be demonstrated by extensive screening (Figure
IC). In these cases, aneuploid nuclei were present as individual
cells or in small tumour cell islets (with an estimated individual-
ized frequency of 1:100-1:1000 reactive cells), showing gain of
centromeric signals >4 and concomitant intranuclear hetero-
geneity, as required by definition.
DISCUSSION
Numerical aberrations of chromosome 8 were only infrequently
reported by metaphase karyotyping studies of exocrine pancreatic
carcinomas. In our report, we show that relative loss or gain ofthe
centromeric region ofchromosome 8 (indicative ofwhole chromo-
some loss or gain respectively) may be a prominent feature of
metastatic pancreatic carcinoma.
A region-specific probe to 8q24 (MYC) was selected to analyse
chromosome 8 aberrations in metastatic effusions in more detail.
To date, only few data on MYC amplification in pancreatic carci-
noma are available. Yamada et al (1986) found amplification ofthe
MYC oncogene in one primary pancreatic carcinoma, as well as in
its metastasis, and Sakorafas et al (1995) reported expression of
MYC by immunohistochemistry in two often cases. In our series,
two effusions with chromosome 8 imbalance showed MYC ampli-
fication, whereas the other cases had concordant signal numbers
with the centromeric and the 8q24-specific probes. Over-represen-
tation of MYC was thus demonstrated in five out often malignant
pancreatic effusions, when the specimens with relative increase of
chromosome 8 copy number were included (see Table 2).
Previous cytogenetic studies differ in the reported frequencies
ofgain of8q in primary pancreatic carcinomas. Solinas-Toldo et al
(1996) found gain of 8q in 3 of 27 primary tumours, whereas
Fukushige et al (1997) reported gain of 8q in three of six primary
tumours and 11 of 12 cell lines. Summarizing these results and the
results from metaphase cytogenetic studies, gain of 8q appears to
be part of the cytogenetic profile of at least some primary pancre-
atic carcinomas. Thus, MYC may already be over-represented in
primary pancreatic carcinomas, and another locus may be the main
target for numerical aberrations of chromosome 8 in metastasizing
pancreatic cancer cells.
Besides aberrations of chromosome 8, metastatic pancreatic
carcinomas are characterized by a generally higher frequency
of chromosomal imbalances and higher ploidy designations
compared with primary tumours. The more extensive genetic
alterations in metastatic disease can be explained by mitotic
malsegregation and endoreduplication, which continue to occur
during solid tumour development, leading to accumulation of
numerical chromosomal imbalances in the former case and
increase in DNA content to hyperploidy in the latter (Dutrillaux
et al, 1991). Endoreduplication, accompanying tumour progres-
sion, may also turn monosomy 18 of primary carcinomas into
'relative loss' of chromosome 18, which was indeed observed
in one metastatic specimen (E4; relative loss of a chromosome
means under-representation in relation to the defined ploidy,
whereas monosomy indicates the presence of a single copy of this
chromosome).
As chromosome 18 was reported to be frequently aberrant in
metaphase cytogenetic studies of pancreatic carcinoma, this chro-
mosome was targeted in all two-colour FISH experiments,
excluding MYC studies and studies of micrometastasis detection.
Four out of 22 pancreatic tumour specimens (primary tumours and
effusion cell samples) exhibited relative loss of chromosome 18,
a frequency (18%) lower than the frequency determined by
metaphase karyotyping (Johansson et al, 1992; Bardi et al, 1993;
Griffin et al, 1994, 1995) and approximating the results obtained
by comparative genomic hybridization for loss of 18q (Solinas-
Toldo et al, 1996; Fukushige et al, 1997). Loss of 18q may be one
mechanism of inactivation of the recently identified tumour-
suppressor gene DPC4 (Hahn et al, 1996).
One particular focus of our work is to establish applications of
FISH for diagnostic procedures in the clinical setting (Fiegl et al,
1995; Schenk et al, 1997; Zojer et al, 1997). In this study, we
show that hyperdiploidy and intranuclear chromosomal hetero-
geneity are a constant finding in metastatic pancreatic cancer. This
suggests that cohybridization with two centromeric probes may be
a useful approach for unequivocal detection of rare (micro)
metastatic cells, e.g. in effusions, peritoneal washings or bone
marrow specimens.
We tested the implication of interphase FISH for malignant cell
detection in effusions from patients with pancreatic cancer by
comparing FISH results with data obtained by cytological examina-
tion. When extensive evaluation by screening of>10 000 nuclei from
each effusion was used, FISH could detect rare aneuploid nuclei in
three cytologically negative effusions, thus pointing to malignancy.
As we demonstrated previously, FISH is a useful adjunct to cytolog-
ical examination ofeffusions from breast cancer patients (Zojeret al,
1997). This also seems to be true for pancreatic cancer patients,
although without statistical confirmation in this series.
Antibodies to cytokeratin are now commonly used for detection
of micrometastatic cells in bone marrow of breast, colon and
pancreatic cancer patients (Cote et al, 1991; Lindemann et al,
1992; Juhl et al, 1994). However, it was reported recently that
some ofthese cytokeratin-positive bone marrow cells may actually
be normal diploid cells of epithelial origin (Litle et al, 1997). We
therefore propose to use FISH as a tool to unequivocally detect
spread of pancreatic cancer to potential metastatic sites (e.g. peri-
toneal cavity, bone marrow), which may enhance further specifica-
tion ofprognostic subgroups ofthis disease.
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